CCCC
C4 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.76
+0.53%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.21
- Revenue estimate
- $8.8M
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.18
- EPS estimate
- -$0.23
- Revenue actual
- $6.6M
- Revenue estimate
- $4.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +12.4%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $12
- PT range
- $12 – $12
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026